$GOSS News

Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks

Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160

Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $90

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio Announces 1-For-80 Reverse Stock Split, Effective September 10

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio announces $250m in funding to advance seralutinib

Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

Gossamer Bio Enters Into Securities Purchase Agreement For Up to $250M Structured Private Placement

Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib

Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4